RE:Quick SummarySo here's an interesting thought (admitedly, way in front of POC). But what if this initial trial shows that Sortilin is what they say it is -- one of THE most advantageous doorways into solid cancer tumor cells. Advantageous because some of those tumors highly overexpress it the worse off the cancer is, and that it quickly internalizes it and negates the MDR1 efflux --both highly valuable traits for a receptor target. And, as PL stated, they are THE leader in SORT1 technology and their patented peptide is the key that opens that doorway that so many others have tried to open, but only found fairly limited targets or targets that work for one type of cancer only, or that maybe aren't as flexible in payload or have that 2x payload capability.
If so, what is that worth? Also, you really shouldn't sell the company if your biggest advantage is in the delivery system and peptide. It's worth vastly more for you to partner up with all the big cancer players for programs with their individual payloads and combinations. In fact, selling out really negates that advantage and your ability to use it widely with all the various types of tumor cell destroying approaches out there that are known now or being worked on in the future. It takes it away from the marketplace as opposed to an independent player having it available across the board to experiment with.
scarlet1967 wrote: Oncology:
As per new dose escalation slide they dosed first patient with 30mg/m2 second patient 2x30mg/m2=60mg/m2 third patient 2x60mg/m2=120mg/m2 forth patient 1.67x120mg/m2=200mg/m2 fifths patient 200mg/m2x1.5=300mg/m2 and last single and sixth patient 300mg/m2x1.4=420mg/m2, it seems they have started dosing group of 3 patients at 420mg/m2 if no DLT planning to increase the dosage by factor of 1.33(420mg/m2x1.33)560mg/m2 on next group of 3 if DLT they dose a group of 6 if less than 1or more with DLT they increase the dosage by factor of 1.33 again in next group of 6 patients until 1 or more patient shows DLT. He confirmed even at twice the level of Docetaxel their intracellular concentration of anti-cancer agent could be multiples of Docetaxel alone theoretically up to 8 time more.
It looks like the amount of Docetaxel released in blood stream in humans is similar to animals based are incoming data which they haven’t published but are monitoring. Paul mentioned they will be starting the combination therapy (TH19 series+ immunotherapy) possibilities in clinic. Their peptide can potentially conjugate to SN-38 a very potent cytotoxic agent and small interfering RNA (molecule which can regulate and effect the expression of genes) in order to silence the protein responsible for cancer cells growth.
NASH:
They are having conversations with few potential partners failing that they want to fund the trial in a responsible manner without effecting the investors negatively.
They have a commercial business which can be used as a collateral in order to raise funds. Also they will be finding the trial in in installments ”chops of payments” so there is no need to raise huge amount of funds initially.
Legacy drugs:
They are optimistic on Tesamorelin as it seems both passed sales and incoming prescription are rising and Trogarzo (long lasting drug) which “seems to be more relevant now” will be launched in multiple European countries once the pricing is confirmed